Carl Schmid provides an update to the NAIC on copay accumulator litigation, including the government’s recent move to appeal and seek clarification from the court and the need for state and federal enforcement that copay assistance, in most instances, must count.
Carl Schmid, along with fellow NAIC Consumer Reps, provide an update to Insurance Commissioners on federal issues including proposed changes to standard plans, , reminders to issuers against using discriminatory plan design, and an update on transparency in coverage requirements and Congressional consideration of PBM regulation.
Carl Schmid discusses how the district court decision that HHS must require insurers to count copay assistance towards patient out-of-pocket costs helps to make prescription drugs more affordable and accessible for patients.
Carl Schmid discusses litigation victory for patients brought by the HIV+Hepatitis Policy Institute and diabetes groups in which the judge struck down the federal rule allowing insurers to not count copay assistance toward patient out-of-pocket costs.
Carl Schmid discusses NC Blue Cross Blue Shield’s decision to remove HIV drugs from the highest and costliest drug tiers following a discrimination complaint filed by the HIV+Hepatitis Policy Institute and NC AIDS Action Network.